Baseline patient characteristics by disease group
| . | MPN-AP (n = 10) . | MPN-BP (n = 15) . | Total (N = 25) . |
|---|---|---|---|
| Age (range), y | 70.1 (46.7-85.6) | 71.6 (52.4-81.4) | 71.0 (46.7-85.6) |
| Female/male, n (%) | 7 (70)/3 (30) | 7 (46.7)/8 (53.3) | 14 (56)/11 (44) |
| ECOG 0-1, n (%) | 5 (50) | 12 (80) | 17 (68) |
| ECOG 2-3, n (%) | 5 (50) | 3 (20) | 8 (32) |
| Disease duration before therapy (range), mo | 41.8 (0.1-190.5) | 74.8 (0.7-177.3) | 72.9 (0.1-190.5) |
| Spleen by palpation (range), cm | 8.0 (0-20) | 6.0 (0-20.0) | 7.0 (0-20.0) |
| Prior ruxolitinib, n (%) | 3 (30.0) | 3 (20) | 6 (24) |
| Prior decitabine, n (%) | 2 (20.0) | 0 (0) | 2 (8) |
| Peripheral blood blasts (range), % | 12.0 (0-18.8) | 34 (0-91) | 17.9 (0-91) |
| Bone marrow blasts (range), % | 7.3 (0-15) | 28.0 (5.0-91.0) | 15.0 (0.0-91.0) |
| Maximum of PB/BM blasts (range), % | 12.5 (10.0-18.8) | 45.0 (20.9-91.0) | 25.0 (10.0-91.0) |
| WBC count (range), ×109/L | 6.0 (3.0-131.1) | 8.7 (1.0-68.2) | 6.6 (1.0-131.1) |
| Hematocrit (range), % | 25.9 (21.6-34.4) | 26.2 (22.4-37.4) | 26.1 (21.6-37.4) |
| Platelet count (range), ×109/L | 160.5 (44-1519) | 39.0 (5-1166) | 76.0 (5-1519) |
| Driver mutation present*, n (%) | 8 (80.0) | 10 (71.4) | 18 (75) |
| Abnormal karyotype†, n (%) | 8 (88.9) | 12 (85.7) | 20 (87) |
| . | MPN-AP (n = 10) . | MPN-BP (n = 15) . | Total (N = 25) . |
|---|---|---|---|
| Age (range), y | 70.1 (46.7-85.6) | 71.6 (52.4-81.4) | 71.0 (46.7-85.6) |
| Female/male, n (%) | 7 (70)/3 (30) | 7 (46.7)/8 (53.3) | 14 (56)/11 (44) |
| ECOG 0-1, n (%) | 5 (50) | 12 (80) | 17 (68) |
| ECOG 2-3, n (%) | 5 (50) | 3 (20) | 8 (32) |
| Disease duration before therapy (range), mo | 41.8 (0.1-190.5) | 74.8 (0.7-177.3) | 72.9 (0.1-190.5) |
| Spleen by palpation (range), cm | 8.0 (0-20) | 6.0 (0-20.0) | 7.0 (0-20.0) |
| Prior ruxolitinib, n (%) | 3 (30.0) | 3 (20) | 6 (24) |
| Prior decitabine, n (%) | 2 (20.0) | 0 (0) | 2 (8) |
| Peripheral blood blasts (range), % | 12.0 (0-18.8) | 34 (0-91) | 17.9 (0-91) |
| Bone marrow blasts (range), % | 7.3 (0-15) | 28.0 (5.0-91.0) | 15.0 (0.0-91.0) |
| Maximum of PB/BM blasts (range), % | 12.5 (10.0-18.8) | 45.0 (20.9-91.0) | 25.0 (10.0-91.0) |
| WBC count (range), ×109/L | 6.0 (3.0-131.1) | 8.7 (1.0-68.2) | 6.6 (1.0-131.1) |
| Hematocrit (range), % | 25.9 (21.6-34.4) | 26.2 (22.4-37.4) | 26.1 (21.6-37.4) |
| Platelet count (range), ×109/L | 160.5 (44-1519) | 39.0 (5-1166) | 76.0 (5-1519) |
| Driver mutation present*, n (%) | 8 (80.0) | 10 (71.4) | 18 (75) |
| Abnormal karyotype†, n (%) | 8 (88.9) | 12 (85.7) | 20 (87) |